Cargando…
Cost–Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy
The objective of this analysis was to estimate the incremental cost–utility ratio (ICUR) of dupilumab as an add-on treatment to best supportive care (BSC), versus BSC alone, in Italy for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). A simulation of outcomes and costs was und...
Autores principales: | De Corso, Eugenio, Furneri, Gianluca, Salsi, Daria, Fanelli, Francesca, Ronci, Gianluca, Sala, Giovanna, Bitonti, Rossella, Cuda, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225649/ https://www.ncbi.nlm.nih.gov/pubmed/35743736 http://dx.doi.org/10.3390/jpm12060951 |
Ejemplares similares
-
Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP
por: Cantone, Elena, et al.
Publicado: (2022) -
WITHDRAWN: Dupilumab: A review of potential in the
treatment of Chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Sree Sudha, T.Y., et al.
Publicado: (2020) -
The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)
por: Hardison, Scott A., et al.
Publicado: (2023) -
Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
por: Anselmo-Lima, Wilma T., et al.
Publicado: (2021) -
Computational fluid dynamic modeling of the effect of dupilumab in the management of anosmia secondary to chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Lepley, Thomas J., et al.
Publicado: (2022)